GSK vs. SOLV: A Head-to-Head Stock Comparison

Updated on November 18, 2025

Here’s a clear look at GSK and SOLV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

GSK trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, SOLV is a standard domestic listing.

Symbol	GSK	SOLV
Company Name	GSK plc	Solventum Corporation
Country	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Health Care Equipment & Supplies
Market Capitalization	95.87 billion USD	13.20 billion USD
Exchange	NYSE	NYSE
Listing Date	March 28, 1980	March 26, 2024
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of GSK and SOLV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

GSK vs. SOLV: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	GSK	SOLV
5-Day Price Return	0.68%	5.39%
13-Week Price Return	25.19%	5.94%
26-Week Price Return	30.94%	2.91%
52-Week Price Return	36.18%	8.02%
Month-to-Date Return	0.20%	9.59%
Year-to-Date Return	32.49%	14.53%
10-Day Avg. Volume	5.00M	1.29M
3-Month Avg. Volume	5.60M	1.03M
3-Month Volatility	24.95%	26.54%
Beta	0.97	0.92

Profitability

Return on Equity (TTM)

GSK

37.40%

Pharmaceuticals Industry

Max: 38.95%
Q3: 20.34%
Median: 11.59%
Q1: 3.32%
Min: -10.91%

In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 37.40% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

SOLV

41.02%

Health Care Equipment & Supplies Industry

Max: 29.82%
Q3: 15.54%
Median: 9.69%
Q1: 5.19%
Min: -7.98%

SOLV’s Return on Equity of 41.02% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

GSK vs. SOLV: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

GSK

17.08%

Pharmaceuticals Industry

Max: 39.07%
Q3: 19.28%
Median: 13.48%
Q1: 5.73%
Min: -8.86%

GSK’s Net Profit Margin of 17.08% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

SOLV

18.13%

Health Care Equipment & Supplies Industry

Max: 24.65%
Q3: 14.10%
Median: 10.09%
Q1: 5.84%
Min: -6.13%

A Net Profit Margin of 18.13% places SOLV in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.

GSK vs. SOLV: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

GSK

23.42%

Pharmaceuticals Industry

Max: 45.58%
Q3: 24.35%
Median: 18.05%
Q1: 7.58%
Min: -11.88%

GSK’s Operating Profit Margin of 23.42% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

SOLV

25.11%

Health Care Equipment & Supplies Industry

Max: 31.34%
Q3: 18.36%
Median: 15.07%
Q1: 9.62%
Min: -0.13%

An Operating Profit Margin of 25.11% places SOLV in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

GSK vs. SOLV: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	GSK	SOLV
Return on Equity (TTM)	37.40%	41.02%
Return on Assets (TTM)	9.13%	10.50%
Net Profit Margin (TTM)	17.08%	18.13%
Operating Profit Margin (TTM)	23.42%	25.11%
Gross Profit Margin (TTM)	72.52%	54.18%

Financial Strength

Current Ratio (MRQ)

GSK

0.84

Pharmaceuticals Industry

Max: 5.45
Q3: 2.99
Median: 1.98
Q1: 1.29
Min: 0.78

GSK’s Current Ratio of 0.84 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

SOLV

1.50

Health Care Equipment & Supplies Industry

Max: 4.97
Q3: 2.92
Median: 2.12
Q1: 1.54
Min: 0.86

SOLV’s Current Ratio of 1.50 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

GSK vs. SOLV: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

GSK

1.10

Pharmaceuticals Industry

Max: 1.79
Q3: 0.78
Median: 0.31
Q1: 0.08
Min: 0.00

GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.10. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

SOLV

1.03

Health Care Equipment & Supplies Industry

Max: 1.62
Q3: 0.74
Median: 0.47
Q1: 0.15
Min: 0.00

SOLV’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 1.03. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

GSK vs. SOLV: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

GSK

2.37

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 10.15
Q1: 2.37
Min: -42.71

GSK’s Interest Coverage Ratio of 2.37 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

SOLV

2.65

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 24.86
Median: 9.84
Q1: 3.86
Min: -21.65

In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s Interest Coverage Ratio of 2.65 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

GSK vs. SOLV: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	GSK	SOLV
Current Ratio (MRQ)	0.84	1.50
Quick Ratio (MRQ)	0.55	1.14
Debt-to-Equity Ratio (MRQ)	1.10	1.03
Interest Coverage Ratio (TTM)	2.37	2.65

Growth

Revenue Growth

GSK vs. SOLV: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

GSK vs. SOLV: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

GSK

3.53%

Pharmaceuticals Industry

Max: 6.72%
Q3: 3.48%
Median: 1.90%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 3.53%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

SOLV

0.00%

Health Care Equipment & Supplies Industry

Max: 4.36%
Q3: 1.87%
Median: 0.82%
Q1: 0.00%
Min: 0.00%

SOLV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

GSK vs. SOLV: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

GSK

46.05%

Pharmaceuticals Industry

Max: 199.58%
Q3: 85.87%
Median: 49.36%
Q1: 1.12%
Min: 0.00%

GSK’s Dividend Payout Ratio of 46.05% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

SOLV

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 67.77%
Median: 28.21%
Q1: 0.00%
Min: 0.00%

SOLV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

GSK vs. SOLV: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	GSK	SOLV
Dividend Yield (TTM)	3.53%	0.00%
Dividend Payout Ratio (TTM)	46.05%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

GSK

13.05

Pharmaceuticals Industry

Max: 52.64
Q3: 29.89
Median: 20.77
Q1: 13.37
Min: 5.71

In the lower quartile for the Pharmaceuticals industry, GSK’s P/E Ratio of 13.05 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

SOLV

8.68

Health Care Equipment & Supplies Industry

Max: 67.59
Q3: 41.41
Median: 33.11
Q1: 22.82
Min: 8.68

In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s P/E Ratio of 8.68 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

GSK vs. SOLV: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

GSK

2.23

Pharmaceuticals Industry

Max: 8.74
Q3: 4.66
Median: 2.37
Q1: 1.67
Min: 0.11

GSK’s P/S Ratio of 2.23 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

SOLV

1.57

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.92
Q1: 1.97
Min: 0.61

In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s P/S Ratio of 1.57 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

GSK vs. SOLV: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

GSK

3.97

Pharmaceuticals Industry

Max: 9.86
Q3: 5.28
Median: 2.48
Q1: 1.57
Min: 0.59

GSK’s P/B Ratio of 3.97 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

SOLV

2.54

Health Care Equipment & Supplies Industry

Max: 10.77
Q3: 6.04
Median: 3.32
Q1: 2.31
Min: 0.83

SOLV’s P/B Ratio of 2.54 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

GSK vs. SOLV: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	GSK	SOLV
Price-to-Earnings Ratio (TTM)	13.05	8.68
Price-to-Sales Ratio (TTM)	2.23	1.57
Price-to-Book Ratio (MRQ)	3.97	2.54
Price-to-Free Cash Flow Ratio (TTM)	15.26	57.46